Bicara Therapeutics Inc.’s Lock-Up Period To End on March 12th (NASDAQ:BCAX)

Bicara Therapeutics’ (NASDAQ:BCAX) lock-up period is set to end on Wednesday, March 12th. Bicara Therapeutics had issued 17,500,000 shares in its IPO on September 13th. The total size of the offering was $315,000,000 based on an initial share price of $18.00. After the end of Bicara Therapeutics’ lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company will be lifted.

Wall Street Analysts Forecast Growth

BCAX has been the topic of a number of recent analyst reports. Wedbush reissued an “outperform” rating and issued a $31.00 price objective on shares of Bicara Therapeutics in a research report on Wednesday, February 12th. HC Wainwright increased their price target on Bicara Therapeutics from $42.00 to $45.00 and gave the stock a “buy” rating in a report on Monday, January 27th. Seven research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Buy” and an average price target of $41.20.

Bicara Therapeutics Stock Performance

Shares of BCAX stock opened at $15.75 on Friday. The stock has a 50-day moving average of $13.56. Bicara Therapeutics has a one year low of $11.10 and a one year high of $28.09.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. First Turn Management LLC purchased a new stake in shares of Bicara Therapeutics in the 3rd quarter worth $14,324,000. The Manufacturers Life Insurance Company bought a new stake in shares of Bicara Therapeutics in the third quarter valued at about $582,000. FMR LLC purchased a new stake in Bicara Therapeutics in the third quarter worth about $57,913,000. Walleye Capital LLC bought a new position in Bicara Therapeutics during the 3rd quarter worth about $809,000. Finally, Vestal Point Capital LP purchased a new position in Bicara Therapeutics during the 3rd quarter valued at about $10,825,000.

About Bicara Therapeutics

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.